Therapeutic antibodies in oncology: an immunopharmacological overview.

Toledo-Stuardo, Karen; Ribeiro, Carolina H.; González-Herrera, Fabiola; Matthies, Douglas J.; Le Roy, María Soledad; Dietz-Vargas, Claudio; Latorre, Yesenia; Campos, Ivo; Guerra, Yuneisy; Tello, Samantha; Vásquez-Sáez, Valeria; Novoa, Pedro; Fehring, Nicolás; González, Mauricio; Rodríguez-Siza, Jose; Vásquez, Gonzalo; Méndez, Pamela; Altamirano, Claudia; Molina, María Carmen

The biotechnological development of monoclonal antibodies and their immunotherapeutic use in oncology have grown exponentially in the last decade, becoming the first-line therapy for some types of cancer. Their mechanism of action is based on the ability to regulate the immune system or by interacting with targets that are either overexpressed in tumor cells, released into the extracellular milieu or involved in processes that favor tumor growth. In addition, the intrinsic characteristics of each subclass of antibodies provide specific effector functions against the tumor by activating antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, among other mechanisms. The rational design and engineering of monoclonal antibodies have improved their pharmacokinetic and pharmacodynamic features, thus optimizing the therapeutic regimens administered to cancer patients and improving their clinical outcomes. The selection of the immunoglobulin G subclass, modifications to its crystallizable region (Fc), and conjugation of radioactive substances or antineoplastic drugs may all improve the antitumor effects of therapeutic antibodies. This review aims to provide insights into the immunological and pharmacological aspects of therapeutic antibodies used in oncology, with a rational approach at molecular modifications that can be introduced into these biological tools, improving their efficacy in the treatment of cancer.

ANTIBODY-dependent cell cytotoxicity; IMMUNOGLOBULIN G; IMMUNE response; BIOTECHNOLOGY; ANTIBODY-drug conjugates; ONCOLOGY

Cancer Immunology, Immunotherapy, 2024, Vol 73, Issue 12, p1

0340-7004

Academic Journal

10.1007/s00262-024-03814-2